Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423801 | 0.77 | — | — | |
| SCHEMBL11312340 | 0.75 | — | — | |
| SCHEMBL13865281 | 0.75 | — | — | |
| SCHEMBL5361784 | 0.75 | — | — | |
| SCHEMBL19895294 | 0.75 | — | — | |
| SCHEMBL6752103 | 0.73 | PYGM (0.34) | — | |
| SCHEMBL5349801 | 0.73 | — | — | |
| SCHEMBL6756889 | 0.72 | PYGM (0.33) | — | |
| SCHEMBL19952738 | 0.71 | — | — | |
| SCHEMBL9693364 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11459310-B2 | LANCL ligands | LANDOS BIOPHARMA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022087146-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220127250-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-113748109-A | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-2266978-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060235002-A1 | Novel physiologically active substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1705247-A1 | DNA PARTICIPATING IN HYDROXYLATION OF MACROLIDE COMPOUND | MERCIAN CORPORATION (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | KDM4E 4239/4885MEN1 2091/4885ALDH1A1 133/4885 |
| US-20220127250-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | KDM4E 3554/4885MEN1 473/4885ALDH1A1 4156/4885 |
| US-20060241171-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | KDM4E 3533/4885MEN1 2851/4885ALDH1A1 108/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | KDM4E 3533/4885MEN1 2851/4885ALDH1A1 108/4885 |
| US-20060235002-A1 | Novel physiologically active substance | HIF1AN, HIF1A, VEGFA | KDM4E 3844/4885MEN1 2966/4885ALDH1A1 119/4885 |
| US-11459310-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | KDM4E 3796/4885MEN1 364/4885ALDH1A1 3541/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | KDM4E 855/4885MEN1 3783/4885ALDH1A1 1391/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | KDM4E 3554/4885MEN1 473/4885ALDH1A1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.